Severely injured trauma patients with admission hyperfibrinolysis: Is there a role of tranexamic acid? Findings from the PROPPR trial

Muhammad Khan, Faisal Jehan, Eileen M. Bulger, Terence O'Keeffe, John B. Holcomb, Charles E. Wade, Martin Schreiber, Bellal Joseph

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    INTRODUCTION Administration of tranexamic acid (TXA) in coagulopathy of trauma gained popularity after the CRASH-2 trial. The aim of our analysis was to analyze the role of TXA in severely injured trauma patients with admission hyperfibrinolysis. METHODS We reviewed the prospectively collected Pragmatic, Randomized Optimal Platelet and Plasma Ratios database. We included patients with admission hyperfibrinolysis (Ly30 >3%) on thromboelastography. Patients were stratified into two groups (TXA and No-TXA) and were matched in 1:2 ratio using propensity score matching for demographics, admission vitals, and injury severity. Primary outcome measures were 6-, 12-, and 24-hour and 30-day mortality; 24-hour transfusion requirements; time to achieve hemostasis; and rebleeding after hemostasis requiring intervention. Secondary outcome measures were thrombotic complications. RESULTS We analyzed 680 patients. Of those, 118 had admission hyperfibrinolysis, and 93 patients (TXA: 31 patients; No-TXA: 62 patients) were matched. Matched groups were similar in age (p = 0.33), gender (p = 0.84), race (p = 0.81), emergency department (ED) Glasgow Coma Scale (p = 0.34), ED systolic blood pressure (p = 0.28), ED heart rate (p = 0.43), mechanism of injury (p = 0.45), head Abbreviated Injury Scale score (p = 0.68), injury severity score (p = 0.56), and blood products ratio (p = 0.44). Patients who received TXA had a lower 6-hour mortality rate (34% vs. 13%, p = 0.04) and higher 24-hour transfusion of plasma (15 vs. 10 units, p = 0.03) compared with the No-TXA group. However, there was no difference in 12-hour (p = 0.24), 24-hour (p = 0.25), and 30-day mortality (p = 0.82). Similarly, there was no difference in 24-hour transfusion of RBC (p = 0.11) or platelets (p = 0.13), time to achieve hemostasis (p = 0.65), rebleeding requiring intervention (p = 0.13), and thrombotic complications (p = 0.98). CONCLUSION Tranexamic acid was associated with increased 6-hour survival but does not improve long-Term outcomes in severely injured trauma patients with hemorrhage who develop hyperfibrinolysis. Moreover, TXA administration was not associated with thrombotic complications. Further randomized clinical trials will identify the subset of trauma patients who may benefit from TXA. LEVEL OF EVIDENCE Therapeutic study, level III.

    Original languageEnglish (US)
    Pages (from-to)851-857
    Number of pages7
    JournalJournal of Trauma and Acute Care Surgery
    Volume85
    Issue number5
    DOIs
    StatePublished - Nov 1 2018

    Fingerprint

    Tranexamic Acid
    Patient Admission
    Wounds and Injuries
    Hemostasis
    Hospital Emergency Service
    Mortality
    Blood Platelets
    Abbreviated Injury Scale
    Outcome Assessment (Health Care)
    Thrombelastography
    Blood Pressure
    Propensity Score
    Glasgow Coma Scale
    Injury Severity Score
    Craniocerebral Trauma
    Research Design
    Randomized Controlled Trials
    Heart Rate

    Keywords

    • Hyperfibrinolysis
    • resuscitation
    • tranexamic acid
    • trauma

    ASJC Scopus subject areas

    • Surgery
    • Critical Care and Intensive Care Medicine

    Cite this

    Severely injured trauma patients with admission hyperfibrinolysis : Is there a role of tranexamic acid? Findings from the PROPPR trial. / Khan, Muhammad; Jehan, Faisal; Bulger, Eileen M.; O'Keeffe, Terence; Holcomb, John B.; Wade, Charles E.; Schreiber, Martin; Joseph, Bellal.

    In: Journal of Trauma and Acute Care Surgery, Vol. 85, No. 5, 01.11.2018, p. 851-857.

    Research output: Contribution to journalArticle

    Khan, Muhammad ; Jehan, Faisal ; Bulger, Eileen M. ; O'Keeffe, Terence ; Holcomb, John B. ; Wade, Charles E. ; Schreiber, Martin ; Joseph, Bellal. / Severely injured trauma patients with admission hyperfibrinolysis : Is there a role of tranexamic acid? Findings from the PROPPR trial. In: Journal of Trauma and Acute Care Surgery. 2018 ; Vol. 85, No. 5. pp. 851-857.
    @article{e78d35408bf84499ba32fed3d426fde0,
    title = "Severely injured trauma patients with admission hyperfibrinolysis: Is there a role of tranexamic acid? Findings from the PROPPR trial",
    abstract = "INTRODUCTION Administration of tranexamic acid (TXA) in coagulopathy of trauma gained popularity after the CRASH-2 trial. The aim of our analysis was to analyze the role of TXA in severely injured trauma patients with admission hyperfibrinolysis. METHODS We reviewed the prospectively collected Pragmatic, Randomized Optimal Platelet and Plasma Ratios database. We included patients with admission hyperfibrinolysis (Ly30 >3{\%}) on thromboelastography. Patients were stratified into two groups (TXA and No-TXA) and were matched in 1:2 ratio using propensity score matching for demographics, admission vitals, and injury severity. Primary outcome measures were 6-, 12-, and 24-hour and 30-day mortality; 24-hour transfusion requirements; time to achieve hemostasis; and rebleeding after hemostasis requiring intervention. Secondary outcome measures were thrombotic complications. RESULTS We analyzed 680 patients. Of those, 118 had admission hyperfibrinolysis, and 93 patients (TXA: 31 patients; No-TXA: 62 patients) were matched. Matched groups were similar in age (p = 0.33), gender (p = 0.84), race (p = 0.81), emergency department (ED) Glasgow Coma Scale (p = 0.34), ED systolic blood pressure (p = 0.28), ED heart rate (p = 0.43), mechanism of injury (p = 0.45), head Abbreviated Injury Scale score (p = 0.68), injury severity score (p = 0.56), and blood products ratio (p = 0.44). Patients who received TXA had a lower 6-hour mortality rate (34{\%} vs. 13{\%}, p = 0.04) and higher 24-hour transfusion of plasma (15 vs. 10 units, p = 0.03) compared with the No-TXA group. However, there was no difference in 12-hour (p = 0.24), 24-hour (p = 0.25), and 30-day mortality (p = 0.82). Similarly, there was no difference in 24-hour transfusion of RBC (p = 0.11) or platelets (p = 0.13), time to achieve hemostasis (p = 0.65), rebleeding requiring intervention (p = 0.13), and thrombotic complications (p = 0.98). CONCLUSION Tranexamic acid was associated with increased 6-hour survival but does not improve long-Term outcomes in severely injured trauma patients with hemorrhage who develop hyperfibrinolysis. Moreover, TXA administration was not associated with thrombotic complications. Further randomized clinical trials will identify the subset of trauma patients who may benefit from TXA. LEVEL OF EVIDENCE Therapeutic study, level III.",
    keywords = "Hyperfibrinolysis, resuscitation, tranexamic acid, trauma",
    author = "Muhammad Khan and Faisal Jehan and Bulger, {Eileen M.} and Terence O'Keeffe and Holcomb, {John B.} and Wade, {Charles E.} and Martin Schreiber and Bellal Joseph",
    year = "2018",
    month = "11",
    day = "1",
    doi = "10.1097/TA.0000000000002022",
    language = "English (US)",
    volume = "85",
    pages = "851--857",
    journal = "Journal of Trauma and Acute Care Surgery",
    issn = "2163-0755",
    publisher = "Lippincott Williams and Wilkins",
    number = "5",

    }

    TY - JOUR

    T1 - Severely injured trauma patients with admission hyperfibrinolysis

    T2 - Is there a role of tranexamic acid? Findings from the PROPPR trial

    AU - Khan, Muhammad

    AU - Jehan, Faisal

    AU - Bulger, Eileen M.

    AU - O'Keeffe, Terence

    AU - Holcomb, John B.

    AU - Wade, Charles E.

    AU - Schreiber, Martin

    AU - Joseph, Bellal

    PY - 2018/11/1

    Y1 - 2018/11/1

    N2 - INTRODUCTION Administration of tranexamic acid (TXA) in coagulopathy of trauma gained popularity after the CRASH-2 trial. The aim of our analysis was to analyze the role of TXA in severely injured trauma patients with admission hyperfibrinolysis. METHODS We reviewed the prospectively collected Pragmatic, Randomized Optimal Platelet and Plasma Ratios database. We included patients with admission hyperfibrinolysis (Ly30 >3%) on thromboelastography. Patients were stratified into two groups (TXA and No-TXA) and were matched in 1:2 ratio using propensity score matching for demographics, admission vitals, and injury severity. Primary outcome measures were 6-, 12-, and 24-hour and 30-day mortality; 24-hour transfusion requirements; time to achieve hemostasis; and rebleeding after hemostasis requiring intervention. Secondary outcome measures were thrombotic complications. RESULTS We analyzed 680 patients. Of those, 118 had admission hyperfibrinolysis, and 93 patients (TXA: 31 patients; No-TXA: 62 patients) were matched. Matched groups were similar in age (p = 0.33), gender (p = 0.84), race (p = 0.81), emergency department (ED) Glasgow Coma Scale (p = 0.34), ED systolic blood pressure (p = 0.28), ED heart rate (p = 0.43), mechanism of injury (p = 0.45), head Abbreviated Injury Scale score (p = 0.68), injury severity score (p = 0.56), and blood products ratio (p = 0.44). Patients who received TXA had a lower 6-hour mortality rate (34% vs. 13%, p = 0.04) and higher 24-hour transfusion of plasma (15 vs. 10 units, p = 0.03) compared with the No-TXA group. However, there was no difference in 12-hour (p = 0.24), 24-hour (p = 0.25), and 30-day mortality (p = 0.82). Similarly, there was no difference in 24-hour transfusion of RBC (p = 0.11) or platelets (p = 0.13), time to achieve hemostasis (p = 0.65), rebleeding requiring intervention (p = 0.13), and thrombotic complications (p = 0.98). CONCLUSION Tranexamic acid was associated with increased 6-hour survival but does not improve long-Term outcomes in severely injured trauma patients with hemorrhage who develop hyperfibrinolysis. Moreover, TXA administration was not associated with thrombotic complications. Further randomized clinical trials will identify the subset of trauma patients who may benefit from TXA. LEVEL OF EVIDENCE Therapeutic study, level III.

    AB - INTRODUCTION Administration of tranexamic acid (TXA) in coagulopathy of trauma gained popularity after the CRASH-2 trial. The aim of our analysis was to analyze the role of TXA in severely injured trauma patients with admission hyperfibrinolysis. METHODS We reviewed the prospectively collected Pragmatic, Randomized Optimal Platelet and Plasma Ratios database. We included patients with admission hyperfibrinolysis (Ly30 >3%) on thromboelastography. Patients were stratified into two groups (TXA and No-TXA) and were matched in 1:2 ratio using propensity score matching for demographics, admission vitals, and injury severity. Primary outcome measures were 6-, 12-, and 24-hour and 30-day mortality; 24-hour transfusion requirements; time to achieve hemostasis; and rebleeding after hemostasis requiring intervention. Secondary outcome measures were thrombotic complications. RESULTS We analyzed 680 patients. Of those, 118 had admission hyperfibrinolysis, and 93 patients (TXA: 31 patients; No-TXA: 62 patients) were matched. Matched groups were similar in age (p = 0.33), gender (p = 0.84), race (p = 0.81), emergency department (ED) Glasgow Coma Scale (p = 0.34), ED systolic blood pressure (p = 0.28), ED heart rate (p = 0.43), mechanism of injury (p = 0.45), head Abbreviated Injury Scale score (p = 0.68), injury severity score (p = 0.56), and blood products ratio (p = 0.44). Patients who received TXA had a lower 6-hour mortality rate (34% vs. 13%, p = 0.04) and higher 24-hour transfusion of plasma (15 vs. 10 units, p = 0.03) compared with the No-TXA group. However, there was no difference in 12-hour (p = 0.24), 24-hour (p = 0.25), and 30-day mortality (p = 0.82). Similarly, there was no difference in 24-hour transfusion of RBC (p = 0.11) or platelets (p = 0.13), time to achieve hemostasis (p = 0.65), rebleeding requiring intervention (p = 0.13), and thrombotic complications (p = 0.98). CONCLUSION Tranexamic acid was associated with increased 6-hour survival but does not improve long-Term outcomes in severely injured trauma patients with hemorrhage who develop hyperfibrinolysis. Moreover, TXA administration was not associated with thrombotic complications. Further randomized clinical trials will identify the subset of trauma patients who may benefit from TXA. LEVEL OF EVIDENCE Therapeutic study, level III.

    KW - Hyperfibrinolysis

    KW - resuscitation

    KW - tranexamic acid

    KW - trauma

    UR - http://www.scopus.com/inward/record.url?scp=85055595985&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85055595985&partnerID=8YFLogxK

    U2 - 10.1097/TA.0000000000002022

    DO - 10.1097/TA.0000000000002022

    M3 - Article

    C2 - 29985230

    AN - SCOPUS:85055595985

    VL - 85

    SP - 851

    EP - 857

    JO - Journal of Trauma and Acute Care Surgery

    JF - Journal of Trauma and Acute Care Surgery

    SN - 2163-0755

    IS - 5

    ER -